FIELD: chemistry.
SUBSTANCE: invention provides a composition for producing a medicament which contains an antibody with a reduced tendency to aggregation owing to introduction of at least one aggregation reducing mutation, selected from a group consisting of residues of aggregation motif - 1:181 (CH1); aggregation motif 4:252 (CH2) and 253 (CH2); aggregation motif 5:282 (CH2); aggregation motif 6:291 (CH2); aggregation motif 7:296 (CH2); aggregation motif 8:308 (CH2) and 309 (CH2); aggregation motif 9:328 (CH2), 329 (CH2), 330 (CH2) and 331 (CH2); aggregation motif 10:395 (CH3), 396 (CH3), 397 (CH3), 398 (CH3) and 404 (CH3); aggregation motif 11:443 (CH3); and aggregation motif 14:201 (CL). Concentration of the antibody is at least 10 mg/ml.
EFFECT: improved immunoglobulins with reduced aggregation.
7 cl, 6 tbl, 9 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHODS OF IDENTIFYING MACROMOLECULE BINDING AND AGGREGATION-PRONE REGIONS IN PROTEINS AND USE THEREOF | 2009 |
|
RU2571217C2 |
| METHOD FOR IDENTIFYING SITES FOR IgG CONJUGATIONS | 2010 |
|
RU2569186C2 |
| OPTIMISING SOLUBILITY OF IMMUNOBINDERS | 2014 |
|
RU2653441C2 |
| OPTIMISING SOLUBILITY OF IMMUNOBINDERS | 2009 |
|
RU2514658C2 |
| SEQUENCE-DEPENDENT AGGREGATION | 2010 |
|
RU2567804C2 |
| METHOD FOR PRODUCTION AND SELECTION OF MOLECULES INCLUDING, AT LEAST TWO DIFFERENT GROUPS, AND APPLICATION THEREOF | 2013 |
|
RU2646159C2 |
| ANTIBODIES TO HUMAN NKG2D AND THEIR APPLICATION | 2008 |
|
RU2563343C2 |
| COVALENTLY LINKED CONJUGATES CHELICAR-ANTIBODY AGAINST CHELICAR AND USE THEREOF | 2014 |
|
RU2694981C2 |
| ANTIBODIES AGAINST INHIBITOR OF TISSUE FACTOR METABOLIC PATHWAY | 2009 |
|
RU2562114C2 |
| ANTIBODY Fc VARIANTS | 2012 |
|
RU2607014C2 |
